These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24560688)

  • 1. Chemical kinetics for drug discovery to combat protein aggregation diseases.
    Arosio P; Vendruscolo M; Dobson CM; Knowles TP
    Trends Pharmacol Sci; 2014 Mar; 35(3):127-35. PubMed ID: 24560688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
    Pain C; Dumont J; Dumoulin M
    Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo aspects of protein folding and quality control.
    Balchin D; Hayer-Hartl M; Hartl FU
    Science; 2016 Jul; 353(6294):aac4354. PubMed ID: 27365453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein misfolding in disease and small molecule therapies.
    Gomes CM
    Curr Top Med Chem; 2012; 12(22):2460-9. PubMed ID: 23339300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies for targeting neurodegenerative protein misfolding disorders.
    Scannevin RH
    Curr Opin Chem Biol; 2018 Jun; 44():66-74. PubMed ID: 29902695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Karyopherin abnormalities in neurodegenerative proteinopathies.
    Pasha T; Zatorska A; Sharipov D; Rogelj B; Hortobágyi T; Hirth F
    Brain; 2021 Nov; 144(10):2915-2932. PubMed ID: 34019093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer and its applications in neurodegenerative diseases.
    Qu J; Yu S; Zheng Y; Zheng Y; Yang H; Zhang J
    Cell Mol Life Sci; 2017 Feb; 74(4):683-695. PubMed ID: 27563707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteria-Derived Protein Aggregates Contribute to the Disruption of Host Proteostasis.
    Walker AC; Bhargava R; Dove AS; Brust AS; Owji AA; Czyż DM
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin.
    Maiti P; Manna J; Veleri S; Frautschy S
    Biomed Res Int; 2014; 2014():495091. PubMed ID: 25386560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of aggregate formation as therapeutic target in protein misfolding diseases: effect of tetracycline and trehalose.
    Sirangelo I; Irace G
    Expert Opin Ther Targets; 2010 Dec; 14(12):1311-21. PubMed ID: 21058920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thermodynamic and kinetic approaches for drug discovery to target protein misfolding and aggregation.
    Vendruscolo M
    Expert Opin Drug Discov; 2023; 18(8):881-891. PubMed ID: 37276120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity.
    Thellung S; Corsaro A; Nizzari M; Barbieri F; Florio T
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phthalocyanines as Molecular Scaffolds to Block Disease-Associated Protein Aggregation.
    Valiente-Gabioud AA; Miotto MC; Chesta ME; Lombardo V; Binolfi A; Fernández CO
    Acc Chem Res; 2016 May; 49(5):801-8. PubMed ID: 27136297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of protein misfolding and aggregation by natural phenolic compounds.
    Dhouafli Z; Cuanalo-Contreras K; Hayouni EA; Mays CE; Soto C; Moreno-Gonzalez I
    Cell Mol Life Sci; 2018 Oct; 75(19):3521-3538. PubMed ID: 30030591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecules that target protein misfolding.
    Gavrin LK; Denny RA; Saiah E
    J Med Chem; 2012 Dec; 55(24):10823-43. PubMed ID: 23075044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathways to polyglutamine aggregation.
    Robertson AL; Bottomley SP
    Adv Exp Med Biol; 2012; 769():115-24. PubMed ID: 23560307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Natural Products as Potential Pharmacological Chaperones for Protein Misfolding Diseases.
    Sharma R; Srivastava T; Pandey AR; Mishra T; Gupta B; Reddy SS; Singh SP; Narender T; Tripathi A; Chandramouli B; Sashidhara KV; Priya S; Kumar N
    ChemMedChem; 2021 Jul; 16(13):2146-2156. PubMed ID: 33760394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade.
    Chiti F; Dobson CM
    Annu Rev Biochem; 2017 Jun; 86():27-68. PubMed ID: 28498720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive review of protein misfolding disorders, underlying mechanism, clinical diagnosis, and therapeutic strategies.
    Basha S; Mukunda DC; Rodrigues J; Gail D'Souza M; Gangadharan G; Pai AR; Mahato KK
    Ageing Res Rev; 2023 Sep; 90():102017. PubMed ID: 37468112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.